No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The company's extensive product portfolio addresses a wide array of medical needs across numerous therapeutic categories. These include pain management (analgesics), conditions such as benign prostatic hyperplasia and various forms of diabetes, neurological disorders like epilepsy, anti-inflammatory conditions, hyperparathyroidism, and gastrointestinal issues like those requiring antacids or treatments for gastroenterology. Marksans Pharma also develops solutions for cardiovascular health, hormonal imbalances, oncology, gynecology, and hypertension, alongside producing antibiotics, antifungals, antiulceratives, vitamins, dermatological preparations, cephalosporins, injectables, anti-allergy, and antibacterial medications. Furthermore, the firm offers contract research and manufacturing services. Established in 1992, its corporate headquarters are situated in Mumbai, India.
marksanspharma.comNo one on the platform currently holds MARKSANS.NS.
No tracked institution reports a position in MARKSANS.NS as of their last filing.
No one on the platform has traded MARKSANS.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.8% | 24.5% | 22.9% | — | — | — |
| Rev. Growth % | 12.5% | 16.6% | ||||
| Profit Margin % | 14.2% | 14.0% | 11.1% | |||
| Free Cash Flow Margin % | 11.9% | 5.5% | 5.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $35.7B | +23.1% | $12.55 | $12.10–$13.00 | — | 2 |
| 2028 | $41.1B | +15.1% | $15.25 | $12.68–$16.70 | — | 3 |
| 2029 | $48.3B | +17.6% | $18.40 | $17.68–$18.87 | — | 1 |
| 2030 | $58.2B | +20.5% | $20.40 | $19.60–$20.92 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $3.33 | $3.48 | +4.5% |
| 2026-05-26 | $3.30 | $3.25 | -1.5% |
| 2026-02-05 | $2.40 | $2.50 | +4.2% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| MARKSANS.NSMarksans Pharma Limited | $312.85 | -5.02% | $141.8B | — |
| AARTIPHARM.BOAarti Pharmalabs Limited | $789.30 | -4.55% | $71.2B | — |
| AARTIPHARM.NSAarti Pharmalabs Limited | $789.45 | -4.53% | $71.6B | — |
| FDC.BOFDC Limited | $349.35 | +2.15% | $56.8B | — |
| FDC.NSFDC Limited |
| $349.65 |
| +2.40% |
| $56.9B |
| — |
| SANOFI.BOSanofi India Limited | $3130.25 | +1.63% | $72.1B | — |
| SANOFI.NSSanofi India Limited | $3131.90 | +1.71% | $72.1B | — |
Source: Financial Modeling Prep · peers by sector/industry